Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).

breast cancer risk prediction risk stratification screening

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
04 Jun 2021
Historique:
received: 04 05 2021
revised: 28 05 2021
accepted: 31 05 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Early detection of breast cancer through screening reduces breast cancer mortality. The benefits of screening must also be considered within the context of potential harms (e.g., false positives, overdiagnosis). Furthermore, while breast cancer risk is highly variable within the population, most screening programs use age to determine eligibility. A risk-based approach is expected to improve the benefit-harm ratio of breast cancer screening programs. The PERSPECTIVE I&I (Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation) project seeks to improve personalized risk assessment to allow for a cost-effective, population-based approach to risk-based screening and determine best practices for implementation in Canada. This commentary describes the four inter-related activities that comprise the PERSPECTIVE I&I project. 1: Identification and validation of novel moderate to high-risk susceptibility genes. 2: Improvement, validation, and adaptation of a risk prediction web-tool for the Canadian context. 3: Development and piloting of a socio-ethical framework to support implementation of risk-based breast cancer screening. 4: Economic analysis to optimize the implementation of risk-based screening. Risk-based screening and prevention is expected to benefit all women, empowering them to work with their healthcare provider to make informed decisions about screening and prevention.

Identifiants

pubmed: 34199804
pii: jpm11060511
doi: 10.3390/jpm11060511
pmc: PMC8226444
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Government of Canada through Genome Canada and Canadian Institutes of Health Research, Ministère de l'Économie et de l'Innovation du Québec through Genome Québec, Quebec Breast Cancer Foundation, CHU de Quebec Foundation and Ontario Research Fund
ID : 13529

Références

Nat Commun. 2020 Jul 31;11(1):3833
pubmed: 32737321
Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455
pubmed: 27507769
J Med Screen. 2019 Sep;26(3):154-161
pubmed: 30572782
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130476
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
Front Genet. 2017 Sep 21;8:128
pubmed: 28983318
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
J Clin Oncol. 2016 Aug 20;34(24):2914-24
pubmed: 27325848
J Natl Cancer Inst. 2020 Apr 1;112(4):400-409
pubmed: 31233138
Prev Med. 2011 Sep;53(3):131-3
pubmed: 21658405
Genet Med. 2020 Mar;22(3):622-632
pubmed: 31636395
Cochrane Database Syst Rev. 2013 Jun 04;(6):CD001877
pubmed: 23737396
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
J Natl Cancer Inst. 2020 Feb 1;112(2):136-144
pubmed: 31233143
PLoS One. 2020 Mar 6;15(3):e0229999
pubmed: 32142536
Eur J Cancer. 2000 Apr;36(6):724-35
pubmed: 10762744
CMAJ Open. 2019 Apr 23;7(2):E272-E282
pubmed: 31018973
JAMA Oncol. 2016 Oct 1;2(10):1295-1302
pubmed: 27228256
J Epidemiol Community Health. 1995 Aug;49(4):413-8
pubmed: 7650466
Nat Genet. 2020 Jan;52(1):56-73
pubmed: 31911677
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473
pubmed: 33335023
Br J Cancer. 2013 Sep 3;109(5):1296-301
pubmed: 23942072
Genet Med. 2021 Jul 6;:
pubmed: 34230637
Nat Genet. 2002 May;31(1):33-6
pubmed: 11984562
Nucleic Acids Res. 2019 Nov 18;47(20):10662-10677
pubmed: 31586400
J Clin Oncol. 2014 Jul 20;32(21):2224-30
pubmed: 24934793
Nat Genet. 2020 May;52(5):466-468
pubmed: 32203466
Ann Intern Med. 2016 Feb 16;164(4):244-55
pubmed: 26756588
J Pers Med. 2021 Feb 02;11(2):
pubmed: 33540785
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Lancet Oncol. 2019 Apr;20(4):504-517
pubmed: 30799262
Health Rep. 2015 Dec;26(12):16-25
pubmed: 26676235
J Genet Couns. 2016 Jun;25(3):472-82
pubmed: 26455498
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Nature. 2014 Sep 4;513(7516):120-3
pubmed: 25141179
BMC Cancer. 2016 Oct 18;16(1):809
pubmed: 27756310
Trends Cancer. 2021 Mar;7(3):188-197
pubmed: 33139182
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274578
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
pubmed: 17392385
CMAJ Open. 2018 Feb 8;6(1):E77-E86
pubmed: 29440151
Cancer. 1977 Jun;39(6 Suppl):2772-82
pubmed: 326378
Food Drug Law J. 2011;66(1):1-24, i
pubmed: 24505844
CMAJ. 2018 Dec 10;190(49):E1432-E1433
pubmed: 30530609
Public Health Genomics. 2013;16(3):94-9
pubmed: 23363703
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
N Engl J Med. 2008 Jun 26;358(26):2796-803
pubmed: 18579814
NPJ Breast Cancer. 2017 Sep 13;3:34
pubmed: 28944288
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
J Natl Cancer Inst. 2021 Mar 1;113(3):329-337
pubmed: 32359158
J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7
pubmed: 10880551
Nat Commun. 2019 Nov 22;10(1):5296
pubmed: 31757951
J Natl Cancer Inst. 1992 May 20;84(10):781-5
pubmed: 1573665
JAMA. 2015 Oct 20;314(15):1615-34
pubmed: 26501537
J Clin Oncol. 2014 Mar 1;32(7):618-26
pubmed: 24449235
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130475
Healthc Policy. 2019 Nov;15(2):39-54
pubmed: 32077844
Sante Publique. 2016 May-Jun;28(3):353-61
pubmed: 27531433
Genet Med. 2020 Nov;22(11):1803-1811
pubmed: 32624571
Maturitas. 2016 Oct;92:150-153
pubmed: 27621253
Curr Oncol. 2017 Dec;24(6):401-406
pubmed: 29270052
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
N Engl J Med. 2015 Jun 11;372(24):2353-8
pubmed: 26039523
CMAJ. 2018 Dec 10;190(49):E1441-E1451
pubmed: 30530611
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Genet Med. 2016 Dec;18(12):1190-1198
pubmed: 27464310
Breast Cancer Res. 2021 Feb 15;23(1):22
pubmed: 33588869
Hum Mutat. 2018 Nov;39(11):1702-1712
pubmed: 30311376
Genet Med. 2020 Oct;22(10):1653-1666
pubmed: 32665703

Auteurs

Jennifer D Brooks (JD)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Hermann H Nabi (HH)

CHU de Québec-Université Laval Research Center, Québec City, QC G1V 4G2, Canada.
Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.
Université Laval Cancer Research Center, Québec City, QC G1R 3S3, Canada.

Irene L Andrulis (IL)

Department of Molecular Genetics, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON M5G 1X5, Canada.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Jocelyne Chiquette (J)

CHU de Québec-Université Laval Research Center, Québec City, QC G1V 4G2, Canada.
Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 4G2, Canada.

Philippe Després (P)

Department of Physics, Engineering Physics and Optics, Faculty of Science and Engineering, Université Laval, Québec City, QC G1V 0A6, Canada.

Peter Devilee (P)

Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Michel Dorval (M)

CHU de Québec-Université Laval Research Center, Québec City, QC G1V 4G2, Canada.
Université Laval Cancer Research Center, Québec City, QC G1R 3S3, Canada.
Faculty of Pharmacy, Université Laval, Québec City, QC G1V 4G2, Canada.
CISSS de Chaudière-Appalaches Research Center, Lévis, QC G6V 3Z1, Canada.

Arnaud Droit (A)

Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 4G2, Canada.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Andrea Eisen (A)

Sunnybrook Health Science Center, Toronto, ON M4N 3M5, Canada.

Laurence Eloy (L)

Programme Québécois de Cancérologie, Ministère de la Santé et des Services Sociaux, Québec City, QC G1S 2M1, Canada.

Samantha Fienberg (S)

Ontario Health, Cancer Care Ontario, Toronto, ON M5G 2L3, Canada.

David Goldgar (D)

Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

Eric Hahnen (E)

Centre for Familial Breast and Ovarian Cancer, Center for Integrated Oncology, Medical Faculty, University Hospital Cologne, 50937 Köln, Germany.

Yann Joly (Y)

Centre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Bartha Maria Knoppers (BM)

Centre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Aisha Lofters (A)

Women's College Research Institute, Toronto, ON M5G 1N8, Canada.

Jean-Yves Masson (JY)

CHU de Québec-Université Laval Research Center, Québec City, QC G1V 4G2, Canada.
Université Laval Cancer Research Center, Québec City, QC G1R 3S3, Canada.

Nicole Mittmann (N)

Sunnybrook Health Science Center, Toronto, ON M4N 3M5, Canada.
Canadian Agency for Drugs and Technologies in Health, Toronto, ON M5H 3Y9, Canada.

Jean-Sébastien Paquette (JS)

Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 4G2, Canada.

Nora Pashayan (N)

Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London WC1E 6BT, UK.

Rita Schmutzler (R)

Centre for Familial Breast and Ovarian Cancer, Center for Integrated Oncology, Medical Faculty, University Hospital Cologne, 50937 Köln, Germany.

Tracy Stockley (T)

Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Sean V Tavtigian (SV)

Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

Meghan J Walker (MJ)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Ontario Health, Cancer Care Ontario, Toronto, ON M5G 2L3, Canada.

Michael Wolfson (M)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

Anna Maria Chiarelli (AM)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Ontario Health, Cancer Care Ontario, Toronto, ON M5G 2L3, Canada.

Jacques Simard (J)

CHU de Québec-Université Laval Research Center, Québec City, QC G1V 4G2, Canada.
Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 4G2, Canada.

Classifications MeSH